Abstract
Epidermal growth factor (EGF) and its receptor (EGFR) as well as the EGFR-coupled Ras > Raf > MEK > ERK pathway are known to affect the survival of cancer cells upon chemotherapeutic treatment. In the present investigation, we analyzed the role of EGFR signaling pathways for the activity of artesunate towards cancer cells. The microarray-based mRNA expression of genes involved in EGFR signaling pathway was correlated with the 50% inhibition concentrations (IC50) of 55 tumor cell lines for artesunate. The log10IC50 values were in a range of -6.609 to -4.0M. Candidate genes identified by this approach were then experimentally validated by transfecting cell lines with corresponding cDNA vectors and treating them with artesunate. Indeed, we observed that the Ras > Raf > MEK > ERK pathway is an important signaling route for the response of tumor cells to artesunate. As exemplarily shown for artesunate, the application of such a combined approach to identify signal transduction pathways involved in the response of tumor cells to cytotoxic compounds might foster the development of novel molecular targeted therapies for cancer treatment.
Keywords: Artesunate, cancer, chemotherapy, EGFR, molecular pharmacology, natural products
Current Cancer Drug Targets
Title: The Role of Downstream Signaling Pathways of the Epidermal Growth Factor Receptor for Artesunates Activity in Cancer Cells
Volume: 9 Issue: 1
Author(s): V. Badireenath Konkimalla, James A. McCubrey and Thomas Efferth
Affiliation:
Keywords: Artesunate, cancer, chemotherapy, EGFR, molecular pharmacology, natural products
Abstract: Epidermal growth factor (EGF) and its receptor (EGFR) as well as the EGFR-coupled Ras > Raf > MEK > ERK pathway are known to affect the survival of cancer cells upon chemotherapeutic treatment. In the present investigation, we analyzed the role of EGFR signaling pathways for the activity of artesunate towards cancer cells. The microarray-based mRNA expression of genes involved in EGFR signaling pathway was correlated with the 50% inhibition concentrations (IC50) of 55 tumor cell lines for artesunate. The log10IC50 values were in a range of -6.609 to -4.0M. Candidate genes identified by this approach were then experimentally validated by transfecting cell lines with corresponding cDNA vectors and treating them with artesunate. Indeed, we observed that the Ras > Raf > MEK > ERK pathway is an important signaling route for the response of tumor cells to artesunate. As exemplarily shown for artesunate, the application of such a combined approach to identify signal transduction pathways involved in the response of tumor cells to cytotoxic compounds might foster the development of novel molecular targeted therapies for cancer treatment.
Export Options
About this article
Cite this article as:
Konkimalla Badireenath V., McCubrey A. James and Efferth Thomas, The Role of Downstream Signaling Pathways of the Epidermal Growth Factor Receptor for Artesunates Activity in Cancer Cells, Current Cancer Drug Targets 2009; 9 (1) . https://dx.doi.org/10.2174/156800909787314020
DOI https://dx.doi.org/10.2174/156800909787314020 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Oxidative Stress in Tumor Angiogenesis - Therapeutic Targets
Current Pharmaceutical Design Inhibition of Cdc42-Interacting Protein 4 (CIP4) Impairs Osteosarcoma Tumor Progression
Current Cancer Drug Targets Targeting mTOR: Evaluating the Therapeutic Potential of Resveratrol for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Current Neuropharmacology Regulatory Triangle of Neurodegeneration, Adult Neurogenesis and MicroRNAs
CNS & Neurological Disorders - Drug Targets Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Dimebon Attenuates the Aβ-Induced Mitochondrial Permeabilization
Current Alzheimer Research The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Destroying RNA as a Therapeutic Approach
Current Medicinal Chemistry Neurorescue Activity, APP Regulation and Amyloid-β Peptide Reduction by Novel Multi-Functional Brain Permeable Iron- Chelating- Antioxidants,M-30 and Green Tea Polyphenol, EGCG
Current Alzheimer Research Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics
Current Pharmaceutical Design Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy Targeting the Pleiotrophin/Receptor Protein Tyrosine Phosphatase β /ζ Signaling Pathway to Limit Neurotoxicity Induced by Drug Abuse
Mini-Reviews in Medicinal Chemistry Recent Advances in Diagnostic and Therapeutic Approaches for Breast Cancer: A Comprehensive Review
Current Pharmaceutical Design Metal Catalyzed Oxidation of Alpha-Synuclein – A Role for Oligomerization in Pathology?
Current Alzheimer Research Glaucoma Pathogenesis and Neurotrophins: Focus on the Molecular and Genetic Basis for Therapeutic Prospects
Current Neuropharmacology Matter of Life and Death: the Pharmacological Approaches Targeting Apoptosis in Brain Diseases
Current Pharmaceutical Design Heterocyclic Chalcone Analogues as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Central Serotonin2C Receptor: From Physiology to Pathology
Current Topics in Medicinal Chemistry